Featured Research
from universities, journals, and other organizations
C. difficile vaccine proves safe, 100 percent effective in animal models
Date:
July 31, 2014
Source:
American Society for Microbiology
Summary:
An experimental vaccine
protected 100 percent of animal models against the highly infectious and
virulent bacterium, Clostridium difficile, which causes an intestinal
disease that kills approximately 30,000 Americans annually.
Elderly patient
(stock image). An experimental vaccine protected 100 percent of animal
models against the highly infectious and virulent bacterium, Clostridium
difficile, which causes an intestinal disease that kills approximately
30,000 Americans annually.
Credit: © 06photo / Fotolia
An experimental vaccine protected 100 percent of animal models against the highly infectious and virulent bacterium, Clostridium difficile,
which causes an intestinal disease that kills approximately 30,000
Americans annually. The research is published ahead of print in Infection and Immunity.
In the study, the vaccine protected the mice and non-human primates against the purified toxins produced by C. difficile, as well as from an orogastric spore infection, a laboratory model that mimics the human disease, after only two immunizations.
"Animals that received two immunizations did not get sick or show signs of C. difficile-associated disease," says corresponding author Michele Kutzler, of Drexel University College of Medicine, Philadelphia.
"While our research was conducted in animal models, the results are very translatable to the clinic," says Kutzler. "In some cases, patients who acquire C. difficile can develop serious complications including severe diarrhea, toxic megacolon, bowel perforation, multi-organ failure, and death. Once fully developed, our DNA vaccine could prevent the deadly effects of C. difficile infection when administered to hospital patients at risk of acquiring C. difficile."
The protection following just two immunizations is especially important since the time window in humans between colonization with C. difficile and the onset of disease symptoms can be a mere 10-14 days, says Kutzler.
The vaccine protects against the bacterial toxins by mustering anti-toxin neutralizing antibodies, says Kutzler.
The cost of fighting the half million C. difficile infections that occur annually in the US is estimated to be nearly $10 billion, most of which could be saved by a successful preventive vaccine, says Kutzler. Morbidity and mortality have risen over the last decade, likely due to increased prevalence of relapsing disease, and hypervirulent strains, she adds.
Treating the disease is especially difficult, as the bacterial spores persist in the hospital environment, where most infections occur. There is no standard, effective treatment for recurrent disease, but a small number of experimental fecal transplants for C. difficile have had a very high success rate, with no adverse reactions.
"Since our vaccine was safe, effective after only two immunizations, and performed exceptionally well, we feel that this success warrants further studies using human patients," says Kutzler.
"Animals that received two immunizations did not get sick or show signs of C. difficile-associated disease," says corresponding author Michele Kutzler, of Drexel University College of Medicine, Philadelphia.
"While our research was conducted in animal models, the results are very translatable to the clinic," says Kutzler. "In some cases, patients who acquire C. difficile can develop serious complications including severe diarrhea, toxic megacolon, bowel perforation, multi-organ failure, and death. Once fully developed, our DNA vaccine could prevent the deadly effects of C. difficile infection when administered to hospital patients at risk of acquiring C. difficile."
The protection following just two immunizations is especially important since the time window in humans between colonization with C. difficile and the onset of disease symptoms can be a mere 10-14 days, says Kutzler.
The vaccine protects against the bacterial toxins by mustering anti-toxin neutralizing antibodies, says Kutzler.
The cost of fighting the half million C. difficile infections that occur annually in the US is estimated to be nearly $10 billion, most of which could be saved by a successful preventive vaccine, says Kutzler. Morbidity and mortality have risen over the last decade, likely due to increased prevalence of relapsing disease, and hypervirulent strains, she adds.
Treating the disease is especially difficult, as the bacterial spores persist in the hospital environment, where most infections occur. There is no standard, effective treatment for recurrent disease, but a small number of experimental fecal transplants for C. difficile have had a very high success rate, with no adverse reactions.
"Since our vaccine was safe, effective after only two immunizations, and performed exceptionally well, we feel that this success warrants further studies using human patients," says Kutzler.
Story Source:
The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.
The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.
Journal Reference:
- S. M. Baliban, A. Michael, B. Shammassian, S. Mudakha, A. S. Khan, S. Cocklin, I. Zetner, B. P. Latimer, L. Bouillaut, M. Hunter, P. Marx, N. Y. Sardesai, S. L. Welles, J. M. Jacobson, D. B. Weiner, M. A. Kutzler. An Optimized, Synthetic DNA Vaccine Encoding the Toxin A and Toxin B Receptor Binding Domains of Clostridium difficile Induces Protective Antibody Responses In Vivo. Infection and Immunity, 2014; DOI: 10.1128/IAI.01950-14
Cite This Page:
American
Society for Microbiology. "C. difficile vaccine proves safe, 100
percent effective in animal models." ScienceDaily. ScienceDaily, 31 July
2014. .
Share This
More Health & Medicine News
Thursday, July 31, 2014
Featured Research
from universities, journals, and other organizations
C. Difficile Vaccine Proves Safe, 100 Percent Effective in Animal Models
July 31, 2014 — An experimental vaccine
protected 100 percent of animal models against the highly infectious and
virulent bacterium, Clostridium difficile, which causes an intestinal
disease that kills approximately ... full story
- C. Difficile Vaccine 100% Effective in Animals
- New Leads for Liver Disease Treatments
- The 'Memory' of Starvation Is in Your Genes
- Insular Cortex Alterations in Mouse Models ...
- Formation of Fingers Explained by Math Theory
- 'Rewired' Mice Show Signs of Longer Lives
- Rare Genetic Disorders in People With Many ...
- Lead in Teeth Can Tell a Body's Tale
- Effect of Loud Noises On Brain Revealed
- Monoamine Oxidase A: Postpartum Depression
newer top stories | older top stories
Featured Videos
from AP, Reuters, AFP, and other news services
House Republicans Vote to Sue Obama Over Healthcare Law
Despite Health Questions, E-Cigs Are Beneficial: Study
Dangerous Bacteria Kills One in Florida
Health Insurers' Profits Slide
No comments:
Post a Comment
Please leave a comment-- or suggestions, particularly of topics and places you'd like to see covered